Wealth Enhancement Advisory Services LLC Acquires 887 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Wealth Enhancement Advisory Services LLC increased its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 126,603 shares of the medical research company’s stock after acquiring an additional 887 shares during the quarter. Wealth Enhancement Advisory Services LLC’s holdings in Thermo Fisher Scientific were worth $65,863,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently bought and sold shares of the company. Hudson Valley Investment Advisors Inc. ADV increased its holdings in Thermo Fisher Scientific by 1.3% in the 4th quarter. Hudson Valley Investment Advisors Inc. ADV now owns 20,331 shares of the medical research company’s stock valued at $10,577,000 after buying an additional 268 shares during the period. Legacy Private Trust Co. increased its holdings in Thermo Fisher Scientific by 1.8% in the 4th quarter. Legacy Private Trust Co. now owns 11,912 shares of the medical research company’s stock valued at $6,197,000 after buying an additional 205 shares during the period. First Hawaiian Bank increased its holdings in Thermo Fisher Scientific by 3.0% in the 4th quarter. First Hawaiian Bank now owns 4,158 shares of the medical research company’s stock valued at $2,163,000 after buying an additional 122 shares during the period. Douglas Lane & Associates LLC increased its holdings in Thermo Fisher Scientific by 1.9% in the 4th quarter. Douglas Lane & Associates LLC now owns 182,511 shares of the medical research company’s stock valued at $94,948,000 after buying an additional 3,460 shares during the period. Finally, Fulton Bank N.A. increased its holdings in Thermo Fisher Scientific by 3.7% in the 4th quarter. Fulton Bank N.A. now owns 8,161 shares of the medical research company’s stock valued at $4,246,000 after buying an additional 288 shares during the period. 89.23% of the stock is owned by institutional investors.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on the stock. TD Cowen raised their price target on shares of Thermo Fisher Scientific from $656.00 to $686.00 in a research note on Tuesday, October 22nd. StockNews.com downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, January 6th. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a research note on Friday. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $655.00 to $680.00 and gave the company an “overweight” rating in a research note on Friday, September 20th. Finally, Robert W. Baird reduced their price target on shares of Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating on the stock in a research note on Thursday, October 24th. Five analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $650.52.

Thermo Fisher Scientific Stock Down 0.4 %

Shares of TMO opened at $542.97 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $493.30 and a 12 month high of $627.88. The company has a current ratio of 1.63, a quick ratio of 1.26 and a debt-to-equity ratio of 0.64. The stock’s 50-day moving average price is $529.91 and its two-hundred day moving average price is $567.91. The company has a market capitalization of $207.69 billion, a PE ratio of 34.04, a PEG ratio of 3.54 and a beta of 0.76.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $5.28 EPS for the quarter, beating the consensus estimate of $5.25 by $0.03. The business had revenue of $10.60 billion for the quarter, compared to the consensus estimate of $10.63 billion. Thermo Fisher Scientific had a return on equity of 17.49% and a net margin of 14.48%. Thermo Fisher Scientific’s revenue for the quarter was up .2% on a year-over-year basis. During the same quarter in the prior year, the business earned $5.69 earnings per share. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 21.68 EPS for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th will be given a dividend of $0.39 per share. The ex-dividend date of this dividend is Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.29%. Thermo Fisher Scientific’s dividend payout ratio is currently 9.78%.

Thermo Fisher Scientific declared that its board has approved a share buyback plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares repurchase plans are usually an indication that the company’s leadership believes its shares are undervalued.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $560.16, for a total value of $168,048.00. Following the transaction, the executive vice president now owns 16,663 shares of the company’s stock, valued at approximately $9,333,946.08. This represents a 1.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total transaction of $5,302,600.00. Following the completion of the transaction, the chief executive officer now directly owns 111,192 shares in the company, valued at approximately $58,960,669.92. The trade was a 8.25 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 47,150 shares of company stock worth $25,954,465 over the last 90 days. Corporate insiders own 0.34% of the company’s stock.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.